Cyclophosphamide induces type I interferon and augments the number of CD44(hi) T lymphocytes in mice: Implications for strategies of chemoimmunotherapy of cancer

Blood

Volumn 95, Issue 6, 2000, Pages 2024-2030

  Schiavoni, Giovanna ^a   Mattei, Fabrizio ^a   Di Pucchio, Tiziana ^a   Santini, Stefano M ^a   Bracci, Laura ^a   Belardelli, Filippo ^a   Proietti, Enrico ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD44V ANTIGEN; CYCLOPHOSPHAMIDE; INTERFERON;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CELL SURVIVAL; IMMUNOMODULATION; LYMPHOCYTE PROLIFERATION; MEMORY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL;

EID: 0034653477     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.6.2024     Document Type: Article

References (54)

1. Hill DL. A Review of Cyclophosphamide. Springfield, IL: C. C. Thomas; 1975.
2. Martin-Suarez I, D'Cruz D, Mansoor M, Fernandes AP, Khamashta MA, Hughes GR. Immuno-suppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamide. Ann Rheum Dis. 1997;56: 481.
3. Gold JE, Ross SD, Krellenstein DJ, LaRosa F, Malamud SC, Osband ME. Adoptive transfer of ex vivo activated memory T-cells with or without cyclophosphamide for advanced metastatic melanoma: results in 36 patients. Eur J Cancer. 1995; 31A:698.
4. Gold JE, Malamud SC, LaRosa F, Osband ME. Adoptive chemoimmunotherapy using ex vivo activated memory T-cells and cyclophosphamide: tumor lysis syndrome of a metastatic soft tissue sarcoma. Am J Hematol. 1993;44:42.
5. Abrams JS, Eiseman JL, Melink TJ, et al. Immunomodulation of interleukin-2 by cyclophosphamide: a phase IB trial. J Immunother 1993; 14:56.
6. + T cells, infusional interleukin-2, and cyclophosphamide in patients with advanced cancer. J Clin Oncol. 1998;16:2752.
7. + 2 T Cells. J Exp Med. 1985;161:1122.
8. Hengst JCD, Mokyr MB, Dray S. Importance of timing in cyclophosphamide therapy of MOPC-315 tumor-bearing mice. Cancer Res. 1980;40: 2135.
9. Vidovic D, Marusic M, Çulo F. Interference of anti-tumor and immunosuppressive effects of cyclophosphamide in tumor-bearing rats. Cancer Immunol Immunother. 1982;14:36.
10. Turk JL, Parker D. Effect of cyclophosphamide on immunological control mechanism, Immunol Rev. 1982;65:99.
11. Kedar E, Ben-Aziz R, Epstein E, Leshem B. Chemoimmunotherapy of murine tumors using interleukin-2 (IL-2) and cyclophosphamide. Cancer Immunol Immunother. 1989;29:74.
12. Katsanis E, Bausero MA, Ochoa AC, et al. Importance in timing of cyclophosphamide on the enhancement of interleukin-2-induced cytolysis. Cancer Immunol Immunother. 1991;34:74.
13. Laude M, Russo KL, Mokyr MB, Dray S. Cure of mice bearing a late-stage, highly metastatic, drug-resistant tumor by adoptive chemoimmunotherapy. Cancer Immunol Immunother. 1993;36: 220.
14. Evans R. Combination therapy by using cyclophosphamide and tumor-sensitized lymphocytes: a possible mechanism of action. J Immunol. 1983;130:2511.
15. Mitchell MS. Combining chemotherapy with biological response modifiers in treatment of cancer. J Natl Cancer Inst. 1989;80:1445.
16. Ootsu K, Gotoh K, Houkan T. Therapeutic efficacy of human recombinant interleukin-2 (TGP-3) alone or in combination with cyclophosphamide and immunocompetent cells in allogeneic, semi-syngeneic, and syngeneic murine tumors. Cancer Immunol Immunother. 1989;30:71
17. Kedar E, Rutkowski Y, Leshem B. Chemo-immunotherapy of murine solid tumors: enhanced therapeutic effects by interleukin-2 combined with interferon α and the role of specific T cells Cancer Immunol Immunother. 1992;35:63.
18. Gold JE, Zachary DT, Osband ME. Adoptively transferred ex vivo activated memory T cells with cyclophosphamide: effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma. Clin Immunol Immunopathol. 1994;73:115.
19. Gold JE, Zachary DT, Osband ME Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma, Int J Cancer. 1995;61:580.
20. + T cells plus cyclophosphamide and liposome-encapsulated interleukin-2 cure murine MC-38 and 3LL tumors and establish tumor-specific immunity. Blood. 1997;89: 2529.
21. Awwad M, North RJ. Cyclophosphamide (Cy)-facilitated adoptive immunotherapy of a Cy-resistant tumour: evidence that Cy permits the expression of adoptive T-cell mediated immunity by removing suppressor T cells rather than by reducing tumour burden, Immunol. 1988;65:87.
22. Reissmann T, Voegeli R, Pohl J, Hilgard P. Augmentation of host antitumor immunity by low doses of cyclophosphamide and mafosfamide in two animal tumor models. Cancer Immunol Immmunother. 1989;28:179.
23. + T cells to cause regression of an advanced lymphoma. Immunol. 1990; 71:90.
24. Hoover SK, Barret SK, Turk TMT, Lee TC, Bear HD. Cyclophosphamide and abrogation of tumor-induced suppressor T cell activity. Cancer Immunol Immunother. 1990;31:121.
25. + T cells in mice bearing an advanced sarcoma augments the antitumor action of interteukin-2. Cancer Immunol Immunother. 1994;38:107.
26. Bloom BR, Modlin RL, Salgame P. Stigma variations: observations on suppressor T cells and leprosy. Annu Rev Immunol. 1992;10:453.
27. Proietti E, Greco G, Garrone B, et al. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice. J Clin Invest. 1998;101:429.
28. Tough DF, Borrow P, Sprent J. Induction of bystander T cell proliferation by viruses and type I Interferon in vivo. Science. 1996;272:1947.
29. Sprent J, Tough DF, Sun S. Factors controlling the turnover of T memory cells, Immunol Rev. 1997;156:79.
30. Gresser I, Tovey MG, Mandu M-T, Maury C, Brouty-Boyé D. Role of interferon in the pathogenesis of virus diseases in mice as demonstrated by the use of anti-interferon serum. I. Rapid evolution of encephalomyocarditis-virus infection. J Exp Med. 1976;144:1305.
31. Gresser I, Belardelli F, Maury C, Maunory MT, Tovey MG. Injection of mice with antibody to interferon enhances the growth of transplantable murine tumors. J Exp Med, 1983;158:2095.
32. + T cells by semiprofessional antigen-presenting cells in vivo. J Exp Med. 1992; 176:1291.
33. Tough DF, Sprent J. Turnover of naive- and memory-phenotype T cells. J Exp Med. 1994;179: 1127.
34. Tovey MG, Begon-Lours J, Gresser I. A method for large scale production of a potent interferon preparation. Proc Soc Exp Biol Med. 1974;146: 609.
35. Ferrantini M, Proietti E, Santodonato L, et al. Alpha1 interferon gene transfer into metastatic Friend leukemia cells abrogated tumorigenicity in immunocompetent mice: antitumor therapy by means of interferon-producing cells. Cancer Res. 1993;53:1107.
36. Rozera C, Carlei D, Lollini PL, et al. Interferon (IFN)-β gene transfer into TS/A adenocarcinoma cells and comparison with IFN-alpha: differential effects on tumorigenicity and host response. Am J Pathol. 1999;154:1211.
37. Dumont FJ, Coker LZ. Interferon-α/β enhances the expression of Ly-6 antigens on T cells in vivo and in vitro. Eur J Immunol. 1986;16:735.
38. Harris J, Sengar D, Stewart T, Hyslop D. The effect of immunosuppressive chemotherapy on immune function in patients with malignant disease. Cancer. 1976;37:1058.
39. Testa U, Martucci R, Rutella S, et al. Autologous stem cell transplantation: release of early and late acting growth factors relates with hematopoietic ablation and recovery. Blood. 1994;84:3532.
40. Inagawa H, Nishizawa T, Honda T, Nakamoto T, Takagi K, Soma G. Mechanisms by which chemotherapeutic agents augment the antitumor effects of tumor necrosis factor: involvement of the pattern shift of cytokines from Th2 to Th1 in tumor lesions. Anticancer Res. 1998;18:3957.
41. Greco G, Gabriele L, Rozera C, Venditti M, Belardelli F, Proietti E. Correlation between the sensitivity or resistance to IL-2 and the response to cyclophosphamide of 4 tumors transplantable in the same murine host, Int J Cancer. 1995;61:1.
42. + T cells. J Surg Oncol. 1998;67:221.
43. Apostolopoulos V, Popovski V, McKenzie IF. Cyclophosphamide enhances the CTL precursor frequency in mice immunized with MUC1-mannan fusion protein (M-FP). J Immunother. 1998; 21:109.
44. Belardelli F, Gresser I. The neglected role of type I Interferon in the T cell response: implications for its clinical use. Immunol Today. 1996;17: 369.
45. Fradelizi D, Gresser I. Interferon inhibits the generation of allospecific suppressor T lymphocytes. J Exp Med. 1982;155:1610.
46. Romagnani S. Induction of Th1 and Th2 responses: a key role of the "natural" immune response? Immunol Today. 1992;13:251.
47. Rogge L, Barberis-Maino L, Biffi M, et al. Selective expression of an interleukin-12 receptor component by human T helper 1 cells. J Exp Med. 1997;185:825.
48. + T cells after injection of tumor cells expressing IFN-α1 into syngeneic mice. Cancer Res. 1998;58:5795.
49. Atlan-Gepner C, Bouabdallah R, Valero R, Coso D, Vialettes B. A cyclophosphamide-induced autoimmune diabetes. Lancet. 1998;352: 373.
50. Fabris P, Betterle C, Greggio NA, et al. Insulin-dependent diabetes mellitus during alpha-interferon therapy for chronic viral hepatitis. J Hepatol. 1998;28:514.
51. Fattovich G, Giustina G, Favarato S, Ruol A. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol. 1996;24:38.
52. + T lymphocytes are required for the synergistic action of interferon-alpha/beta and adoptively transferred immune cells in the inhibition of visceral ESb metastases. Cancer Res. 1995;55:6133.
53. Sun S, Zhang X, Tough DF, Sprent J. Type I interferon-mediated stimulation of T cells by CpG DNA. J Exp Med. 1998;188:2335.
54. Tough DF, Sprent J. Bystander stimulation of T cells in vivo by cytokines. Vet Immunol Immunopathol. 1998;63:123.